PIEZO1 and breast carcinoma: Barh demonstrated that in silico analysis, apart from repressing HMGA2, RAS, and MYC, let-7 may also target CYP19A1, ESR1, and ESR2, thereby potentially blocking estrogen signaling in ER-positive breast cancers [28].